• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在微生理系统早期开发中考虑未来监管科学资质:芯片上血管中微血栓形成的案例研究

Considering future qualification for regulatory science in the early development of microphysiological systems: a case study of microthrombosis in a Vessel-on-Chip.

作者信息

Weener Huub J, Middelkamp Heleen H T, Van der Meer Andries D

机构信息

Bioengineering Technologies, University of Twente, Enschede, Netherlands.

Institute for Human Organ and Disease Model Technologies (hDMT), Eindhoven, Netherlands.

出版信息

Front Toxicol. 2024 Dec 6;6:1513002. doi: 10.3389/ftox.2024.1513002. eCollection 2024.

DOI:10.3389/ftox.2024.1513002
PMID:39713185
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11659250/
Abstract

Microphysiological systems (MPS) and Organs-on-Chips (OoCs) hold significant potential for replicating complex human biological processes . However, their widespread adoption by industry and regulatory bodies depends on effective qualification to demonstrate that these models are fit for purpose. Many models developed in academia are not initially designed with qualification in mind, which limits their future implementation in end-user settings. Here, we explore to which extent aspects of qualification can already be performed during early development stages of MPS and OoCs. Through a case study of our blood-perfused Vessel-on-Chip model, we emphasize key elements such as defining a clear context-of-use, establishing relevant readouts, ensuring model robustness, and addressing inherent limitations. By considering qualification early in development, researchers can streamline the progression of MPS and OoCs, facilitating their adoption in biomedical, pharmaceutical, and toxicological research. In addition, all methods must be independent of animal-derived materials to be considered fully fit for purpose. Ultimately, early qualification efforts can enhance the availability, reliability, and regulatory as well as ethical acceptance of these emerging New Approach Methodologies.

摘要

微生理系统(MPS)和器官芯片(OoC)在复制复杂的人类生物过程方面具有巨大潜力。然而,它们在行业和监管机构中的广泛应用取决于有效的鉴定,以证明这些模型符合用途。许多在学术界开发的模型最初在设计时并未考虑鉴定问题,这限制了它们未来在终端用户环境中的应用。在这里,我们探讨在MPS和OoC的早期开发阶段,鉴定的各个方面在多大程度上已经可以进行。通过对我们的血液灌注芯片血管模型的案例研究,我们强调了关键要素,如定义明确的使用背景、建立相关的读数、确保模型的稳健性以及解决固有局限性。通过在开发早期考虑鉴定,研究人员可以简化MPS和OoC的进展,促进它们在生物医学、制药和毒理学研究中的应用。此外,所有方法必须独立于动物源性材料,才能被认为完全符合用途。最终,早期的鉴定工作可以提高这些新兴新方法的可用性、可靠性、监管以及伦理接受度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd58/11659250/492c7b423217/ftox-06-1513002-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd58/11659250/9b99f26e644c/ftox-06-1513002-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd58/11659250/492c7b423217/ftox-06-1513002-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd58/11659250/9b99f26e644c/ftox-06-1513002-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd58/11659250/492c7b423217/ftox-06-1513002-g002.jpg

相似文献

1
Considering future qualification for regulatory science in the early development of microphysiological systems: a case study of microthrombosis in a Vessel-on-Chip.在微生理系统早期开发中考虑未来监管科学资质:芯片上血管中微血栓形成的案例研究
Front Toxicol. 2024 Dec 6;6:1513002. doi: 10.3389/ftox.2024.1513002. eCollection 2024.
2
A path forward advancing microphysiological systems.推进微生理系统的前进道路。
ALTEX. 2025;42(2):183-203. doi: 10.14573/altex.2504091.
3
Circadian hormone control in a human-on-a-chip: In vitro biology's ignored component?芯片上的人体昼夜节律激素调控:体外生物学中被忽视的部分?
Exp Biol Med (Maywood). 2017 Nov;242(17):1714-1731. doi: 10.1177/1535370217732766.
4
Biology-inspired dynamic microphysiological system approaches to revolutionize basic research, healthcare and animal welfare.受生物学启发的动态微生理系统方法,旨在彻底改变基础研究、医疗保健和动物福利。
ALTEX. 2025;42(2):204-223. doi: 10.14573/altex.2410112. Epub 2025 Jan 17.
5
Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development.受生物学启发的微生理系统可提高药物开发中患者获益和动物福利。
ALTEX. 2020;37(3):365-394. doi: 10.14573/altex.2001241. Epub 2020 Feb 28.
6
The Current Status and Use of Microphysiological Systems by the Pharmaceutical Industry: The International Consortium for Innovation and Quality Microphysiological Systems Affiliate Survey and Commentary.制药行业中微生理系统的现状和应用:国际创新和质量微生理系统联盟附属调查及评论。
Drug Metab Dispos. 2024 Feb 14;52(3):198-209. doi: 10.1124/dmd.123.001510.
7
Opportunities and challenges for human microphysiological systems in drug development.人体微生理系统在药物研发中的机遇与挑战。
ALTEX. 2025;42(2):224-256. doi: 10.14573/altex.2409221. Epub 2024 Dec 20.
8
Microphysiological systems in early stage drug development: Perspectives on current applications and future impact.微生理系统在药物早期开发中的应用:当前应用及未来影响的展望。
J Toxicol Sci. 2021;46(3):99-114. doi: 10.2131/jts.46.99.
9
Academic User View: Organ-on-a-Chip Technology.学术用户视角:芯片上器官技术。
Biosensors (Basel). 2022 Feb 16;12(2):126. doi: 10.3390/bios12020126.
10
Advancements in Microphysiological systems: Exploring organoids and organ-on-a-chip technologies in drug development -focus on pharmacokinetics related organs.微生理系统的进展:探索类器官和芯片器官技术在药物开发中的应用——聚焦于与药代动力学相关的器官。
Drug Metab Pharmacokinet. 2025 Feb;60:101046. doi: 10.1016/j.dmpk.2024.101046. Epub 2024 Dec 17.

引用本文的文献

1
Fetal bovine serum: how to leave it behind in the pursuit of more reliable science.胎牛血清:如何在追求更可靠科学的过程中将其摒弃。
Front Toxicol. 2025 Aug 8;7:1612903. doi: 10.3389/ftox.2025.1612903. eCollection 2025.

本文引用的文献

1
A bispecific antibody approach for the potential prophylactic treatment of inherited bleeding disorders.双特异性抗体方法可用于潜在的遗传性出血性疾病的预防性治疗。
Nat Cardiovasc Res. 2024 Feb;3(2):166-185. doi: 10.1038/s44161-023-00418-4. Epub 2024 Feb 8.
2
Synthesis of bioengineered heparin chemically and biologically similar to porcine-derived products and convertible to low MW heparin.化学合成和生物学方法制备与猪源产品类似的生物工程肝素,并可转化为低分子量肝素。
Proc Natl Acad Sci U S A. 2024 Apr 2;121(14):e2315586121. doi: 10.1073/pnas.2315586121. Epub 2024 Mar 18.
3
Preparation of a universally usable, animal product free, defined medium for 2D and 3D culturing of normal and cancer cells.
制备一种通用的、无动物产品的、用于正常细胞和癌细胞二维及三维培养的限定培养基。
MethodsX. 2024 Feb 3;12:102592. doi: 10.1016/j.mex.2024.102592. eCollection 2024 Jun.
4
Heads on! Designing a Qualification Framework for Organ-on-Chip.正面交锋!设计芯片器官资格框架。
ALTEX. 2024;41(2):320-323. doi: 10.14573/altex.2401231. Epub 2024 Jan 23.
5
Towards in vitro models for reducing or replacing the use of animals in drug testing.致力于开发体外模型以减少或替代药物测试中动物的使用。
Nat Biomed Eng. 2024 Aug;8(8):930-935. doi: 10.1038/s41551-023-01154-7.
6
Considerations from an International Regulatory and Pharmaceutical Industry (IQ MPS Affiliate) Workshop on the Standardization of Complex In Vitro Models in Drug Development.药物研发中复杂体外模型标准化的国际监管和制药行业(IQ MPS 附属机构)研讨会的思考
Adv Biol (Weinh). 2024 Aug;8(8):e2300131. doi: 10.1002/adbi.202300131. Epub 2023 Oct 9.
7
ISSCR standards for the use of human stem cells in basic research.国际干细胞研究学会人类干细胞基础研究使用标准。
Stem Cell Reports. 2023 Sep 12;18(9):1744-1752. doi: 10.1016/j.stemcr.2023.08.003.
8
Application of Polymethylpentene, an Oxygen Permeable Thermoplastic, for Long-Term on-a-Chip Cell Culture and Organ-on-a-Chip Devices.聚甲基戊烯(一种透氧热塑性塑料)在长期芯片上细胞培养和芯片上器官装置中的应用。
Micromachines (Basel). 2023 Feb 24;14(3):532. doi: 10.3390/mi14030532.
9
Industry Adoption of Organoids and Organs-on-Chip Technology: Toward a Paradox of Choice.行业对类器官和器官芯片技术的采用:走向选择的悖论。
Adv Biol (Weinh). 2023 Jun;7(6):e2200334. doi: 10.1002/adbi.202200334. Epub 2023 Mar 2.
10
Human organs-on-chips for disease modelling, drug development and personalized medicine.用于疾病建模、药物开发和个性化医疗的人体器官芯片。
Nat Rev Genet. 2022 Aug;23(8):467-491. doi: 10.1038/s41576-022-00466-9. Epub 2022 Mar 25.